Plasmodium berghei is used as a rodent model for the study of malaria. However, multiple genetic manipulations are restricted by the paucity of selectable markers. The bsd-blasticidin selection system is widely used for eukaryotic cells; however, it could not previously be used for P. berghei due to toxicity to the rodent host. Here, we report the application of this selection system in P. berghei using an in vitro selection method. The desired bsd-integrated mutants are enriched by more than 90% within 2 weeks when using this system. Furthermore, the bsd marker can be used sequentially with established pyrimethamine-and puromycin-resistant markers. This system allows deeper understanding of malaria parasite biology through extensive genetic manipulation of P. berghei.
Malaria is a global life-threatening disease caused by Plasmodium spp. [1] . Plasmodium berghei is used as a rodent model for the study of malaria because the parasite does not cause malaria in humans and the lifecycle can be completed in a laboratory [2] . The reverse genetics approach has been established in this parasite and has been used to study malaria parasite biology [3, 4] . However, the limited number of selection markers has hampered sequential genetic manipulation methods [5] [6] [7] .
There are three antifolate positive selection markers available in P. berghei: pyrimethamine-resistant P. berghei dihydrofolate reductase-thymidylate synthase (pbdhfr-ts), Toxoplasma gondii dhfr-ts (tgdhfrts), and human dhfr (hdhfr). Pyrimethamine and WR99210 are both antifolates targeting the parasite dihydrofolate reductase [5, 8] . WR99210, also known as BRL6231, a structural analog of antifolate cycloguanil, was developed in the early 1970s and shown to be remarkably effective against pyrimethamine-resistant strains of Plasmodium falciparum [9, 10] . All three markers confer resistance to pyrimethamine, but only hdhfr can confer resistance to WR99210; therefore, in terms of selection systems, hdhfr can be used as a secondary marker in sequential genetic manipulations [5] . However, it is challenging to run sequential genetic manipulation experiments in P. berghei because hdhfr confers slight WR99210 resistance to dhfr-ts-integrated parasites [5] .
Currently, several marker recycling methods based on positive-negative selection and flow sorting have been established to solve this problem; however, these methods are laborious and do not solve the problem of limited number of available positive selection markers [6, 11] . Furthermore, the marker recycling methods cannot be used in sequential manipulation experiments with the mutant parasites established using hdhfr marker, commonly used in past malaria research [2, 12] .
Drug selection of mutant parasites needs to be performed in vivo because P. berghei cannot be propagated in vitro and, therefore, drugs that are toxic to rodent hosts cannot be used. To overcome this problem, we recently developed an in vitro culture drug selection method for P. berghei, based on shortterm in vitro culture with a drug followed by parasite recovery in vivo [12] . The most important advantage of the in vitro method was to enable the use of drugs (such as puromycin) that are toxic for the rodent host. The mode of action for the puromycin system is different than conventional antifolate systems [13] , so that can be used in sequential manipulation with traditional antifolate markers [12] . Another advantage of this in vitro selection method is that the target mutant parasite can be enriched to the desired level (>90%) within 2 weeks. This high selection efficacy allows for the easy isolation of a mutant clone by reducing the number of mice, the amount of time needed, and the cost of the cloning procedure.
The blasticidin S deaminase (bsd) gene is isolated from Aspergillus terreus; it confers blasticidin S (blasticidin) resistance and is widely used for genetic manipulation of eukaryotic cells [14] . Blasticidin inhibits protein synthesis in both prokaryotic and eukaryotic cells. This method has been used in human malaria studies with P. falciparum [15] ; however, it has not been used in P. berghei because of its toxicity to rodent hosts. We solved this host toxicity problem by applying it in our in vitro selection method. We report the establishment of a novel blasticidin selection system using bsd as a marker. Furthermore, we report the first demonstration of triple sequential manipulation in P. berghei using independent positive markers.
Materials and methods

Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for Laboratory Animals from the Obihiro University of Agriculture and Veterinary Medicine. The Committee of Animal Experiments of the Obihiro University of Agriculture and Veterinary Medicine approved the protocol (permit number 29-146).
Experimental animals and parasites
The ICR and BALB/c (5-week-old) mice were obtained from CLEA Japan, inc. (Tokyo, Japan). The BALB/c mice were used for the parasite cloning and growth assays, and the ICR mice were used for the other experiments. We used two parasite strains, the wild-type P. berghei ANKA strain (WT) (obtained from M. Torii, Ehime University) and a strain constitutively expressing GFP (PbDHFR-GFP) [16] (obtained from M. Yuda, Mie University).
Plasmid construct
Elements of the pXL/hdhfr-bsd-egfp plasmid were sequentially ligated into a pXL-BacII-DHFR plasmid backbone [17, 18] . Firstly, the hdhfr expression cassette was excised from pXL-BacII-DHFR, namely, pXL-BacII-DHFR (-). Next, hdhfr was cloned into pXL-BacII-DHFR (-) under control of the P. berghei elongation factor 1 alpha (ef-1a) promoter and the pbdhfr-ts terminator. Then, egfp was excised from the pCX-EGFP Vector [19] under control of the P. berghei hsp70 promoter and terminator. This was cloned into the plasmid pXL-BacII-DHFR (-) that also contained the hdhfr expression cassette. The bsd gene was then excised using pCMV/Bsd (Invitrogen, Carlsbad, CA, USA) under control of the hsp70 promoter and terminator and cloned into the pXL-BacII-DHFR (-) that contained the hdhfr and egfp expression cassettes. The promoters and terminators were excised from a Yuda 2 plasmid (obtained from M. Yuda, Mie University). pXL/hdhfr-bsd-egfp was transected with the transposase expression vector EGF-pgT [12] .
Elements of pBS/bsd were generated into a pBS backbone. The bsd expression cassette was flanked by the hsp70 promoter and terminator.
The correct sequences of all plasmid inserts were confirmed by DNA sequencing using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) (Figs S1 and S2).
Parasite transfection and drug selection in vitro
Parasite transfection experiments followed standard protocols [20] . Briefly, about 1 mL of infected P. berghei blood (1.0-3.0% parasitemia) was cultured in 50 mL of culture medium [RPMI 1640 medium (cat no. 23400-021, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with NaHCO 3 (0.85 gÁL À1 ), neomycin sulfate (50 lgÁL À1 ), and 20% fetal bovine serum (FBS)] for schizonts collection. Schizonts were purified by Nycodenz density gradient centrifugation. Transfection was performed with a Nucleofector 2b device (Lonza, Basel, Switzerland) using a T Cell Nuclofector Kit (Lonza) under the U-33 program [12] . During the piggyBac experiment, the target plasmid was cotransfected with the transposase plasmid EGF-pgT. All in vitro drug selection procedures were performed separately from the in vivo drug selection procedures that used pyrimethamine or WR99210, and basically followed as previously described [12] .
In the piggyBac experiments, approximately 7 lL of infected P. berghei blood was collected from the tail, placed in 0.5 mL of culture medium with 2 lL of heparin solution, and centrifuged at 500 g for 5 min at room temperature (RT). The supernatant was discarded, and the parasites were resuspended in 0.5 mL of culture medium. The suspension (450 lL, parasitemia 0.5-3.0%) was placed into a 24-well plate (Thermo Fisher Scientific), and 50 lL of blasticidin S stock solution (Funakoshi, Osaka, Japan, 5 mgÁmL À1 , dissolved in RPMI 1640 medium) was added to form a final concentration of 500 lgÁmL À1 (approximately fivefold IC 90 value of PBDHFR). The parasites were incubated for approximately 20 h (36.5°C, 5% CO 2 , 5% O 2 , 90% N 2 ). After incubation, the parasites were collected by centrifuging at 500 g for 5 min at RT, resuspended in 100 lL of PBS, and injected intravenously into a na€ ıve mouse. This selection procedure was repeated when the parasitemia reached 0.5-3.0%.
In double-crossover homologous recombination experiments, 200 lL of infected P. berghei blood was collected and placed in 5 mL of culture medium, centrifuged at 500 g for 8 min at RT, and the supernatant was discarded. The blood was resuspended in 10.8 mL of culture medium. The suspension was placed into a 25 cm 2 flask (Thermo Fisher Scientific) with 1.2 mL of blasticidin stock solution to form a final concentration of 500 lgÁmL À1 and a total volume of 12 mL. This suspension was incubated for 20 h. After incubation, the sample was centrifuged at 500 g for 8 min at RT, resuspended in 100 lL of PBS, and injected intravenously into a na€ ıve mouse.
Mutant ratio calculation by microscopy
Parasites were identified with the Hoechst 33342 stain and quantified using fluorescent microscopy as previously described [12] . The parasites were distinguished from white blood cells by fluorescence intensity and morphology of nuclei stained with Hoechst. The mutant ratio was calculated by dividing the number of eGFP-positive parasites by the number of Hoechst-positive parasites. In experiments where transfection was performed with GFP-positive parasites, the mutant ratio was calculated by dividing the number of GFP-negative parasites by the number of Hoechstpositive parasites.
Fluorescence analysis and flow cytometry analysis
Fluorescent images of parasites were obtained using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan) under 400 9 magnification and were analyzed using a BZ-II Analyzer (Keyence). For the flow cytometry analysis, infected P. berghei blood was stained with the cell-permeant DNA dye SYTO59 (Thermo Fisher Scientific) for counter staining, and analyzed with an EPICS ALTRA flow cytometer (Beckman Coulter, Brea, CA, USA) as previously described [12] . Band pass emission filters of 525 nm and 675 nm were used to analyze eGFP and GFP, and SYTO59 fluorescence, respectively.
Drug sensitivity test
Drug sensitivity tests were performed as previously described [5, 21] . Briefly, infected P. berghei blood 
Southern blot analysis
Southern blot analysis was performed as previously described [12] . Genomic DNA was extracted by proteinase K-SDS method [22] . Two micrograms of extracted genomic DNA were digested using EcoRI (Fig. 1) or SpeI (Fig. 2) , separated on a 1% agarose gel, transferred onto a Hybond N + membrane (GE Healthcare, Chalfont St. Giles, UK), and then hybridized with bsd or 3 0 hsp70 probes labeled with AP (AlkPhos Direct Kit, GE Healthcare). The signal was detected using a CDP star (GE Healthcare or Thermo Fisher Scientific). The digital chemiluminescence images were taken by an Ez-Capture MG (ATTO, Tokyo Japan). 1Kb Plus DNA Ladder (Thermo Fisher Scientific) was used as a marker.
Statistical analysis
Statistical analyses comparing each bsd-integrated parasite clone against the wild-type parasite were performed using two-tailed unpaired t-tests. The mutant ratio of each selection was compared using paired t-tests. IC 50 values were calculated using the program GRAPHPAD PRISM ver.5 (GraphPad). Statistical analyses comparing IC 50 values were performed using Dunnett's multiple comparisons tests.
Results
Determination if bsd confers blasticidin resistance to Plasmodium berghei
We analyzed the IC 50 values for blasticidin of wild-type parasites (WT), pyrimethamine-resistant pbdhfr-ts marker-integrated parasites (PBDHFR), and pXL/hdhfr-bsd-egfp-transfected parasites that were selected by pyrimethamine (BSD) (Fig. 1A) (Fig. 1B) . The IC 50 value of BSD tended to be increased, as compared with that of WT (P = 0.0684) and PBDHFR (P = 0.0637). BSD showed significantly decreased susceptibility to blasticidin at the concentrations above the IC 70 value compared with WT and PBDHFR (P < 0.05). Therefore, bsd is functional in P. berghei and can confer blasticidin resistance for the parasite. 
Use of bsd as a selection marker in Plasmodium berghei
Drug sensitivity test described above confirmed that the optimum concentration of blasticidin was 500 lgÁmL À1 (approximately IC 70 value of BSD and fivefold IC 90 value of PBDHFR). The in vitro selection procedure for the pXL/hdhfr-bsd-egfp-transfected parasite was performed three times with the 500 lgÁmL À1 concentration of blasticidin, and the egfp-expressing mutant ratio was monitored after each selection. The ratio was 3.29 AE 1.57, 92.33 AE 1.97, and 94.64 AE 1.98 (Mean AE SD) % after each selection, respectively (Fig. 1C,D) . It took 1-2 days from transfection to first selection (parasitemia 1.89 AE 1.53%), 6-7 days from first to second selection (parasitemia 1.46 AE 0.23%), and 5 days (parasitemia 0.98 AE 0.51%) from second to third selection. Two clones were isolated from the mutant parasites population selected in Fig. 1C by in vivo limiting dilution method to confirm that bsd was integrated into the genome. Southern blot analysis confirmed that bsd was integrated into the genome (Fig. 1E) . Insertion sites of the piggyBac transposon were confirmed by inverse PCR ( Table 1 ). The growth of the two clones was analyzed to determine whether the integration of bsd affected parasite growth. The two clones showed no significant difference from wildtype parasites in vivo (Fig. 1F) . A typical transfection line was also analyzed using flow cytometry. More than 96% of the parasites expressed eGFP after the second selection (Fig. 1G) . Therefore, bsd can be used as a positive selection marker in P. berghei.
Use of a bsd marker for gene targeting
We constructed a targeting vector that contained a bsd expression cassette which replaced the gfp expression cassette of the GFP-expressing mutant (PbDHFR-GFP) [16] through double-crossover homologous recombination ( Fig. 2A) . The targeting vector was transfected to PbDHFR-GFP, and the gfp-negative mutant ratio was monitored after each in vitro selection. The ratio was 4.74 AE 0.99, 6.88 AE 0.69, and 98.57 AE 2.35 (Mean AE SD) % after each selection, respectively (Fig. 2B,C) . It took 2-3 days from transfection to first selection (parasitemia 1.09 AE 0.92%), and 5-6 days from first to second selection (parasitemia 1.80 AE 0.86%). Two clones were isolated and Southern blot analysis confirmed that bsd was integrated into the genome with the expected size (Wild: 11.5 kbp with 3 0 hsp70 probe, GFP: 11.5 kbp and 8.9 kbp with 3 0 hsp70 probe, cl.1 and cl. 2: 7.6 kbp with bsd probe, 11.5 kbp and 7.6 kbp with 3 0 hsp70 probe) (Fig. 2D) . A typical transfection line was also analyzed using flow cytometry. More than 99% of the parasites did not express GFP after the second selection (Fig. 2E) . Therefore, bsd can be used for gene targeting, as well as for random insertion using the piggyBac transposon.
Use of a bsd marker with two established markers
The targeting vector pBS/bsd was transfected to the GFP-expressing spect2 KO parasites containing pac and pbdhfr-ts markers (PbDHFR-GFP+PAC) [12] (Fig. 3A) . The in vitro selection procedure was repeated twice, with the gfp-negative mutant ratio monitored after each selection. The ratio was 3.87 AE 1.77, 8.02 AE 2.39, and 99.29 AE 0.74 (mean AE SD) % after each selection, respectively (Fig. 3B) . The clone PbDHFR+PAC+BSD was isolated. Correct modification of the mutant clone with parasites in each stage was confirmed with Southern blot analysis (Fig. 3C) , fluorescent microscopy (Fig. 3D) , and flow cytometry analysis (Fig. 3E) . Therefore, bsd can be used in sequential triple genetic manipulation with the established pac and traditional pbdhfr-ts markers.
Discussion
Reverse genetics is a powerful method for studying malaria parasite biology through the dissection of target gene function [2] . However, the number of available selection markers has restricted the range of genetic manipulations of P. berghei, emphasizing the need for the establishment of additional selection markers. Soga et al. established an in vitro selection method in order to overcome this problem. In this study, we developed a selection marker in P. berghei that can be used with this in vitro method. Blasticidin S deaminase is a useful selection marker in several organisms [14] . The bsd marker is tractable due to its small size (399 bp), with blasticidin stable in both solid state and in solution (<pH 8.0) [23] . The bsd marker is used in P. falciparum studies, but has not been used in P. berghei studies because of blasticidin toxicity in the rodent host. We solved this problem by applying it in the in vitro selection method.
Plasmodium berghei was shown to be susceptible to blasticidin and bsd is functional in P. berghei. Blasticidin S deaminase did not inhibit growth of two clones AAAATATTTTAA-piggyBac-TTAACAAAAAAG Fig. 3 . Sequential genetic manipulation using three markers. (A) Schematic diagram showing the sequential manipulation using three markers. In the third manipulation, gfp in the GFP-expressing spect2 KO mutant [12] was replaced by bsd through double-crossover homologous recombination. pbdhfr-ts was used to obtain the parent GFP transgenic parasite by in vivo pyrimethamine selection. (B) The GFP-negative parasite ratio after each blasticidin selection. The ratio was analyzed using fluorescence microscopy. Each bar represents the mean AE SD of three independent experiments. ***P < 0.001, *P < 0.05 (paired t-tests). of pXL/hdhfr-bsd-egfp-transfected parasite and conferred an approximate fivefold decrease susceptibility to P. berghei ANKA. Indeed, the desired mutants could be selected by blasticidin at the concentration that BSD showed significantly decreased susceptibility. These results suggest that bsd can be used as a selection marker in P. berghei. The desired bsd-integrated mutant clones were isolated using both random insertion with piggyBac transposon and homologous recombination methods. In the piggyBac experiments, inverse PCR and sequencing analysis of two independent parasite clones identified the unique TTAA piggyBac insertion sites. Southern blot analysis also confirmed a single unique integration occurred in each clones at the identified locus with expected fragment size obtained from PlasmoDB database (http://plasmodb.org/plasmo/). In double-crossover homologous recombination experiments, Southern blot analysis of two isolated clones also confirmed that integration of bsd at the correct gfp locus of parental line through double-crossover homologous recombination. We confirmed that integration of bsd did not affect parasite growth. Therefore, bsd can be used as a selection marker. The bsd-blasticidin selection system was applied to the in vitro selection method together with pac-puromycin and hdhfr-WR99210 [12] , using the different modes of action of each drug. This indicates the universality of the in vitro selection method, and its potential use for further markers [15] .
It was possible to enrich the desired mutants by more than 90% with two repetitions of the selection procedure using the bsd-blasticidin system. This high selection efficacy was comparable to the in vitro pacpuromycin system [12] , and permits the easy cloning of target mutants using in vivo cloning methods with only five mice needed. In traditional methods, two rounds of cloning procedures using more than 30 mice are needed to isolate the mutant parasites. This reduction results in rapid isolation of clones as well as a decrease in cost, time, and labor.
The bsd-blasticidin system provides a useful platform for sequential genetic manipulation, such as generation of multiple gene KO parasites or KO rescue experiments that have been rarely performed [7] . The bsd-blasticidin system is independent from antifolate and puromycin systems [24] , so bsd can be used with traditional antifolate and pac markers. These results suggest that bsd can readily be used in sequential manipulation experiments with the mutant parasites established in past malaria research using any type of selection marker, including reference lines expressing fluorescence protein [25, 26] . This is the first demonstration of sequential genetic manipulation in P. berghei using three independent positive selection markers without marker recycling.
Furthermore, another advantage is that the bsd-blasticidin system permits easy isolation of double mutants together with the pac-puromycin system. In traditional marker recycling methods, more than 100 days are required for double mutant isolation because of the complex process including cloning at each step [6, 27] . However, in our in vitro systems, only one cloning procedure is needed at the final step because of the high selection efficacy. Additionally, negative selection is not required. Therefore, isolation of target double mutants can be obtained within 40 days.
In summary, we establish bsd as a novel selection marker in P. berghei. Furthermore, the bsd marker can be used together with pac and traditional antifolate markers. These results significantly improve the flexibility of genetic manipulation of P. berghei, and thus permit us a deeper understanding of malaria parasite molecular biology using a reverse genetics approach.
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